UK Unveils Go-It-Alone Drug Approval System
Accelerated Reviews Part Of MHRA's Post-Brexit Plans
Special approval procedures for new drugs and biosimilars, more use of real-world data, a streamlined drug safety monitoring system, and a ‘patient-first culture.’ The MHRA has plenty of ideas in store for its post-Brexit life as a fully independent regulator from January next year.
